Innovent Biologics, Inc.
1801
Κατάταξη σε μετοχές
#1152
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Τιμή μετοχής
$11.35
Κεφαλαιοποίηση
$19.80B
Αλλαγή (1 ημέρα)
1.56%
Αλλαγή (1 έτος)
1.55%
Χώρα
CN
Εμπόριο Innovent Biologics, Inc. (1801)
Κατηγορία
Healthcare
Έσοδα για την Innovent Biologics, Inc. (1801)
Έσοδα τον Jun 2026 TTM: $2.26B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Innovent Biologics, Inc., τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $2.26B. Το 2023, η εταιρεία είχε έσοδα $876.74M αύξηση σε σχέση με τα έσοδα του έτους 2022, τα οποία ήταν $660.55M. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Innovent Biologics, Inc. από 2016 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $2.26B | 74.99% |
| 2024 | $1.29B | 47.23% |
| 2023 | $876.74M | 32.73% |
| 2022 | $660.55M | -1.67% |
| 2021 | $671.77M | 14.17% |
| 2020 | $588.40M | 291.13% |
| 2019 | $150.44M | 10,818.89% |
| 2018 | $1.38M | -51.65% |
| 2017 | $2.85M | -38.42% |
| 2016 | $4.63M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $12.62B | 458.89% |
US
|
|
| $2.23B | -1.36% |
US
|
|
| $15.74B | 597.02% |
AU
|
|
| $6.02B | 166.57% |
NL
|
|
| - | - |
CH
|
